Abstract
Women tend to develop hypertension later as they transition into menopause, and during and after menopause the development of hypertension in women is independent of age and body mass index (BMI) but is related to menopause itself. One of the mechanisms of hypertension development in postmenopausal women is believed to be the lack of estrogen leading to vasoconstriction due to both reninangiotensin- aldosterone (RAA)-sensitive and sodium-sensitive pathways. Nowadays, we have many medications of antihypertensive therapy, including angiotensin converting enzyme (ACE) and inhibitor and angiotensin receptor blocker (ARB) in addition to diuretics, beta-blockers, calcium channel blockers. The present review summarizes gender differences in the effects of ARB on blood pressure lowering and cardiovascular outcomes from the published reports of large-scaled, randomized clinical trials and its substudy on sexspecific difference. Many antihypertensive drugs have been developed, and the benefit of blood pressure lowering therapy for the prevention of cardiovascular disease would be expected not only in men but also in women as indicated in the large-scaled clinical studies with ARB.
Keywords: Angiotensin receptor blocker (ARB), Blood pressure lowering, Cardiovascular disease, Gender, Sex-difference, Large-scaled randomized study, Renin-angiotensin-aldosteron (RAA) system, Angiotensin, Renin, Hypertension, SYMPHONY, Androgens, vasopressor, antihypertensive, losartan, amlodipine, angina, NYHA, diastolic, Val-HeFT, non-Hispanic
Current Pharmaceutical Design
Title: Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Volume: 17 Issue: 11
Author(s): Hiroshi Yoshida, Giuseppe Rosano, Mitsuyuki Shimizu, Seibu Mochizuki and Michihiro Yoshimura
Affiliation:
Keywords: Angiotensin receptor blocker (ARB), Blood pressure lowering, Cardiovascular disease, Gender, Sex-difference, Large-scaled randomized study, Renin-angiotensin-aldosteron (RAA) system, Angiotensin, Renin, Hypertension, SYMPHONY, Androgens, vasopressor, antihypertensive, losartan, amlodipine, angina, NYHA, diastolic, Val-HeFT, non-Hispanic
Abstract: Women tend to develop hypertension later as they transition into menopause, and during and after menopause the development of hypertension in women is independent of age and body mass index (BMI) but is related to menopause itself. One of the mechanisms of hypertension development in postmenopausal women is believed to be the lack of estrogen leading to vasoconstriction due to both reninangiotensin- aldosterone (RAA)-sensitive and sodium-sensitive pathways. Nowadays, we have many medications of antihypertensive therapy, including angiotensin converting enzyme (ACE) and inhibitor and angiotensin receptor blocker (ARB) in addition to diuretics, beta-blockers, calcium channel blockers. The present review summarizes gender differences in the effects of ARB on blood pressure lowering and cardiovascular outcomes from the published reports of large-scaled, randomized clinical trials and its substudy on sexspecific difference. Many antihypertensive drugs have been developed, and the benefit of blood pressure lowering therapy for the prevention of cardiovascular disease would be expected not only in men but also in women as indicated in the large-scaled clinical studies with ARB.
Export Options
About this article
Cite this article as:
Yoshida Hiroshi, Rosano Giuseppe, Shimizu Mitsuyuki, Mochizuki Seibu and Yoshimura Michihiro, Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (11) . https://dx.doi.org/10.2174/138161211795656909
DOI https://dx.doi.org/10.2174/138161211795656909 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology A Therapeutic Target for Microvascular Complications in Diabetes: Endothelium- Derived Hyperpolarizing Factor
Current Cardiology Reviews Treatment of Carotid Stenosis
Current Vascular Pharmacology Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Current Pharmaceutical Design The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Biological Activities and Synthetic Approaches of Dihydropyrimidinones and Thiones - An Updated Review
Current Bioactive Compounds The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Should all Hypertensive Patients be Screened for Primary Aldosteronism?
Current Hypertension Reviews The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Editorial (Thematic Issue: Endothelium: A Target for Therapeutic Intervention)
Current Vascular Pharmacology Measuring the Burden of Disease in the United Arab Emirates, 1990 – 2019: A Road to Future
New Emirates Medical Journal